Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?

Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?

The use of surrogate end points as a basis for conclusions about therapy and drugs for cardiovascular disease is both praised and criticized as it has resulted in both successes and failures. Surrogate end points can lead to much faster approval of drugs, but the consequences of relying on such data...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association Vol. 282; no. 8; pp. 790 - 795
Main Author: Temple, Robert
Format: Journal Article
Language:English
Published: United States American Medical Association 25-08-1999
Subjects:
Biomarkers
Cardiovascular Agents - therapeutic use
Cardiovascular disease
Cardiovascular Diseases - prevention & control
Clinical trials
Clinical Trials as Topic
Drug Approval
Drug Evaluation
FDA approval
Humans
Medical research
Pharmaceuticals
Risk
Treatment Outcome
United States
United States Food and Drug Administration
United States
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of surrogate end points as a basis for conclusions about therapy and drugs for cardiovascular disease is both praised and criticized as it has resulted in both successes and failures. Surrogate end points can lead to much faster approval of drugs, but the consequences of relying on such data must be carefully weighed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.282.8.790